- Home
- MASI vs JAZZ Comparison
MASI vs JAZZ Comparison
Compare MASI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MASI | JAZZ |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 10.4B |
| IPO Year | 2000 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MASI | JAZZ |
|---|---|---|
| Price | $178.52 | $204.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $184.00 | ★ $217.57 |
| AVG Volume (30 Days) | 636.9K | ★ 849.8K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.05 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,239,153,000.00 | ★ $1,618,693,000.00 |
| Revenue This Year | $8.59 | $6.22 |
| Revenue Next Year | $7.66 | $7.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.34 | N/A |
| 52 Week Low | $125.94 | $105.00 |
| 52 Week High | $179.00 | $207.48 |
Technical Indicators
Market Signals| Indicator | MASI | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 67.36 | 62.37 |
| Support Level | $176.68 | $159.78 |
| Resistance Level | $178.93 | $207.48 |
| Average True Range (ATR) | 0.24 | 5.16 |
| MACD | -0.42 | -0.04 |
| Stochastic Oscillator | 53.70 | 76.98 |
Price Performance
Historical ComparisonAbout MASI Masimo Corporation
Masimo Corp is a medical technology company. The company oepates in single segment namely Healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. The company sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, and others.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.